AEON Biopharma (AEON) Fundamental Analysis: Revenue, Earnings & Valuation

4.61 / 10

Netural

Fundamental score is 4.6/10, indicating fair health. Strengths include strong accounts‑receivable turnover and interest coverage, while fixed‑asset turnover and tax‑to‑profit ratios lag. Revenue‑to‑market and asset‑to‑market metrics add modest upside, yielding a middling overall rating.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score3/3

Weight42.27%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight2.25%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-2.40%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-2.38%

1M Return-0.65%

PB-ROE

Value-0.09

Score1/3

Weight22.41%

1M Return5.22%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-5.40%

1M Return-1.54%

Fixed assets turnover ratio

Value7899.90

Score1/3

Weight-4.45%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-2.68%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-2.63%

1M Return-0.74%

Asset-MV

Value-0.48

Score2/3

Weight53.02%

1M Return9.91%

Is AEON undervalued or overvalued?

AEON scores 4.61/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -15.78 P/E ratio, -1.30 P/B ratio, and -87.54% earnings growth, these metrics solidify its Netural investment rating.